Navigation Links
Verenium Reports Financial Results For The First Quarter Ended March 31, 2013
Date:5/9/2013

SAN DIEGO, May 9, 2013 /PRNewswire/ -- Verenium Corporation (Nasdaq: VRNM), a leading industrial biotechnology company focused on the development and commercialization of high-performance enzymes, today reported financial results for the first quarter ended March 31, 2013, and also provided full year 2013 financial guidance.

(Logo: http://photos.prnewswire.com/prnh/20120924/MM79973LOGO) Financial ResultsRevenuesRevenues for the quarters ended March 31, 2013 and 2012 were as follows (in thousands):Three Months Ended March 31,20132012Revenues:Animal health and nutrition

$
7,926$
7,416Grain processing

2,1663,585Oilseed processing

--579All other products

124141Total product

10,21611,721Contract manufacturing

2,218--Collaborative and license

1,3525,508Total revenue

$
3,786$
7,229Total revenues for the quarter ended March 31, 2013 decreased 20% to $13.8 million from $17.2 million in the prior year, primarily due to license revenue recorded in 2012 from DSM and Novus International. Combined product and contract manufacturing revenue for the quarter ended March 31, 2013 increased 6% to $12.4 million from $11.7 million in the prior year.

Product revenue for the quarter ended March 31, 2013 decreased 13% to $10.2 million from $11.7 million in the prior year, primarily attributed to a decline in grain processing revenue due to the timing of orders from a major customer, as well as adverse business conditions impacting the corn ethanol industry. The Company also reported lower revenue from its grain processing and oilseed processing product lines as a result of the sale of its Veretase® alpha-amylase and Purifine® PLC enzymes to DSM in March 2012.

In conjun
'/>"/>

SOURCE Verenium Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Verenium Reports Financial Results For The Third Quarter And Nine Months Ended September 30, 2012
2. Verenium To Present At Upcoming Conferences
3. Verenium To Present At The Jefferies 2012 Global Industrial And Aerospace & Defense Conference
4. Verenium To Present At The Deutsche Bank 2012 Clean Tech, Utilities & Power Conference
5. Sequenom, Inc. Reports Financial Results For The First Quarter Of 2013
6. Nektar Therapeutics Reports Financial Results for the First Quarter of 2013
7. Simcere Pharmaceutical Group Reports Preliminary Unaudited First Quarter 2013 Results
8. Chindex International, Inc. Reports First Quarter 2013 Financial Results
9. BioScrip Reports First Quarter 2013 Financial Results
10. China Biologic Reports Financial Results for the First Quarter of 2013
11. Nephros Reports First Quarter 2013 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... YORK , Jan. 15, 2014 ... report is available in its catalogue: ... Forecast – Worldwide Analysis ... Market Analysis Insulin ...
(Date:1/15/2014)... 15, 2014 Reportlinker.com announces that a ... its catalogue: Global ... Systems -- Focus on End Users ... OBJECTIVES A drug delivery system ...
(Date:1/15/2014)... FRANKLIN, Ohio , Jan. 15, 2014  A novel wearable ... it easy and painless for patients to self-inject prescription drugs ... of disorders, including cancer, blood diseases, autoimmune deficiencies, and genetic ... expected to grow to $220B by 2018, according to analysts.   ...
Breaking Medicine Technology:Insulin Pump Market & Forecast - Worldwide Analysis 2Insulin Pump Market & Forecast - Worldwide Analysis 3Insulin Pump Market & Forecast - Worldwide Analysis 4Insulin Pump Market & Forecast - Worldwide Analysis 5Insulin Pump Market & Forecast - Worldwide Analysis 6Insulin Pump Market & Forecast - Worldwide Analysis 7Insulin Pump Market & Forecast - Worldwide Analysis 8Insulin Pump Market & Forecast - Worldwide Analysis 9Insulin Pump Market & Forecast - Worldwide Analysis 10Insulin Pump Market & Forecast - Worldwide Analysis 11Insulin Pump Market & Forecast - Worldwide Analysis 12Insulin Pump Market & Forecast - Worldwide Analysis 13Insulin Pump Market & Forecast - Worldwide Analysis 14Insulin Pump Market & Forecast - Worldwide Analysis 15Insulin Pump Market & Forecast - Worldwide Analysis 16Insulin Pump Market & Forecast - Worldwide Analysis 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2
... VG Energy, a subsidiary of Viral Genetics, Inc. ... that it has retained alternative energy producer BioProcess ... for the development of commercial production of its potential ... with results reproduced multiple times from test-tube to small-pond ...
... 2011 Watson Pharmaceuticals, Inc. (NYSE: WPI ... for the District of Delaware has ruled that Watson,s ... United States Patent No. 6,264,981 (the ,981 Patent).  The ... and would evaluate all available options, including an appeal. ...
Cached Medicine Technology:VG Energy Contracts BioProcess Algae To Verify "Lipid Trigger" Results For Commercial Biofuels Production 2VG Energy Contracts BioProcess Algae To Verify "Lipid Trigger" Results For Commercial Biofuels Production 3VG Energy Contracts BioProcess Algae To Verify "Lipid Trigger" Results For Commercial Biofuels Production 4Watson Confirms District Court Ruling in Generic Fentora® Patent Suit 2
(Date:4/23/2014)... Physical Activity on Mobility Limitation in Old Age , ... of mobility limitation in old age, whereas leisure-time physical ... study which followed up 5,200 public sector employees for ... Research Center in Finland and the Finnish Institute of ... wears the body and lasts for several hours a ...
(Date:4/23/2014)... proliferation of endogenous neural precursor cells cannot alone ... From the perspective of neural plasticity, Dr. Yun ... China observed the effects of functional electrical stimulation ... expression of basic fibroblast growth factor and epidermal ... infarct side. The researchers found that functional electrical ...
(Date:4/22/2014)... Jersey Institute of Technology (NJIT) today to join ... of the New Jersey Innovation Institute (NJII), an ... business innovation through the leveraging of industry, government, ... Cory Booker, Panasonic Corp. of North America Chairman ... Kim Guadagno, New Jersey Secretary of Higher Education ...
(Date:4/22/2014)... provide primary care for low-income patients may ease ... companies while improving patient health, researchers have concluded. ... health clinics that avoid costs associated with insurance ... hospital admission rates and emergency room visits, according ... Altoona. , The researchers estimated that the ...
(Date:4/22/2014)... (SACRAMENTO, Calif.) The risk of pregnancy among women ... sterilization is more than 10 times greater over a ... sterilization, a study by researchers at Yale University and ... in the medical journal Contraception , the study ... sterilization method marketed under the brand name Essure. ...
Breaking Medicine News(10 mins):Health News:Midlife occupational and leisure-time physical activity limits mobility in old age 2Health News:Government and industry leaders herald launch of NJIT's New Jersey Innovation Institute 2Health News:Clinics not bogged down by red tape can ease health cost burdens 2Health News:Risk of pregnancy greater with newer method of female sterilization 2Health News:Risk of pregnancy greater with newer method of female sterilization 3
... (XMRV) has been the subject of many studies since ... an unclear picture of XMRV,s role in human disease. ... issue of The Journal of Infectious Diseases , ... between XMRV and prostate cancer but not other links ...
... TUESDAY, Oct. 12 (HealthDay News) -- Women who maintain certain ... if a close relative has had the disease, a new ... healthy weight and drinking alcohol in moderation, if at all, ... breast cancer in postmenopausal women, the researchers said. "Whether ...
... Phase-II trial investigating a new, targeted therapy for metastatic ... reported at the 35th Congress of the European Society ... cancers affect the tissue lining the inner surfaces of ... In cases of metastatic disease, median survival is approximately ...
... can lead some women to wonder if the risk is ... 85,000 postmenopausal women, published in BioMed Central,s open access journal ... maintaining a healthy weight, and drinking less alcohol lowers breast ... of the disease. The University of Rochester Medical Center ...
... Gardner HealthDay Reporter , MONDAY, Oct. 11 ... in a U.S.-government-approved study involving human embryonic stem cells ... saving cells. The patient, being cared for at ... a spinal cord injury. The center specializes in treating ...
... lead some people to wonder if their risk is out ... postmenopausal women observed that regular physical activity, maintaining a healthy ... women with, and without a family history of the disease. ... Oct. 12, 2010, by the journal Breast Cancer Research ...
Cached Medicine News:Health News:New studies examine links between XMRV and human disease 2Health News:New studies examine links between XMRV and human disease 3Health News:Three Healthy Habits Cut Breast Cancer Risk, Study Finds 2Health News:Three Healthy Habits Cut Breast Cancer Risk, Study Finds 3Health News:Pazopanib shows promise in Phase II trial for relapsed/refractory urothelial cancer 2Health News:First Patient Treated in U.S.-Approved Embryonic Stem Cell Trial 2Health News:First Patient Treated in U.S.-Approved Embryonic Stem Cell Trial 3Health News:Breast-healthy lifestyle worthwhile, URMC study confirms 2
... Massive hemorrhage associated with displaced pelvic fractures ... faced by orthopaedic and trauma surgeons. , ... antishock garment, external fixation, and internal fixation ... Stabilizer has been developed as a method ...
The large External Fixator consists of rods, clamps, and pins. It has multiple external fixation frames, independent pin placement, and MR safe clamps. The modular frame construction permits fracture...
The DFS Standard Fixator advantages include a highly adjustable system, modular compression/distraction, versatile central body component that provides 360 of rotation, and a positive locking mechani...
For radial/ulnar translation, angulation, dorsal/volar translation, and incremental longitudinal distraction, this advanced system is appropriate when incremental adjustment provides an adjunctive me...
Medicine Products: